Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
QuidelOrtho
| Company | QuidelOrtho |
|---|---|
| Name of instrument | VITROS XT 3400 Chemistry Systems |
| Contact | Laura Osborne |
| City, State | Raritan, NJ |
| Phone | 800-828-6316 |
| Website | |
| Type of instrument | chemistry |
| Operational type/Model type | batch, random access, continuous random access, discrete/ floor standing |
| List price/First year sold in U.S. | —/2019 |
| Targeted hospital bed size/Targeted test volume | —/annual: 50,000–4 million |
| Company manufactures instrument | no (manufactured by JABIL; also sold by Cardinal, McKesson, more) |
| Other models in this family of analyzers | VITROS 4600 Chemistry System, VITROS 350 Chemistry System |
| No. of units in clinical use in U.S./Outside U.S. (countries) | > 140/> 225 (North, Central, and South Americas, more) |
| Dimensions (H × W × D)/Instrument footprint | 53 × 58 × 34 in./— |
| Weight empty/Weight fully loaded | 1,150 lbs./— |
| No. of different measured assays onboard simultaneously | 89 (89 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | — |
| Test throughput per hour/Assay run time | 1,130/2.5–9 min. (avg. 5 min.) |
| No. of direct ion-selective electrode channels | 3 |
| Detection methods | photometry, potentiometry, turbidimetry |
| Stat time until completion/specimen throughput for ion-selective electrode | 5 min./126 specimens per hr. |
| Stat time until completion/specimen throughput for basic metabolic panel | 6 min./95 specimens per hr. |
| Stat time until completion/specimen throughput for complete metabolic panel | 7.5 min./74 specimens per hr. |
| Typical time delay from ordering stat test until aspiration of sample | 1 min. |
| Fully automated microplate immunoassay system | — |
| Methodologies supported | — |
| Separation methodologies | — |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Approximate No. of tests per reagent set/Reagent type | 18–120/self-contained single use |
| Reagents refrigerated onboard/Reagents ready to use | yes (10°C)/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | dry chemistry (closed reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/no |
| Walkaway capability/Walkaway duration | yes/— |
| Design of sample-handling system | universal sample tray, continuous load and unload, circular routine sample center |
| Uses washable cuvettes/Uses disposable cuvettes | no/no |
| Min.–max. sample volume that can be aspirated at one time | 2–200 µL |
| Min. reaction volume/Min. specimen volume/Min. dead volume | —/2.5 µL/35 µL |
| Dedicated pediatric sample cup | yes (dead volume: 35 µL) |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/yes (micro sample cups, micro collection containers, 10.25 × 45 mm, 12 × 75 mm, 12 × 100 mm, 13 × 75 mm, more) |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | detection for clots; detection and quantitation for hemolysis, icterus, lipemia |
| Dilutes patient samples onboard/Susceptibility to carryover | yes/0 |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | yes |
| Autocalibration/Multipoint calibration supported | no (calibrants are not stored onboard)/yes (recommended avg. frequency: 6 months or lot change) |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | 6 months/6 months/6 months/6 months or lot change for most chemistry assays/— |
| Automatic programmable start/Automatic programmable shutdown | no/no |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | manually by user |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128, ISBT 128)/yes |
| Lab can control analyzer from remote computer | no |
| Instrument can diagnose its own malfunctions | yes (operator intervention required to order parts) |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | onboard/— |
| LIS interface provided/Bidirectional interface capability | yes (included in instrument price)/yes (broadcast download and host query) |
| Modem servicing provided/Service engineer on-site response time | yes/4 hrs. |
| Mean time between failures | — (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: ~7 min. (incl. automated); weekly: ~10 min.; monthly: ~10 min. |
| Maintenance records kept onboard for user/vendor | yes/yes (both include audit trail of who replaced parts) |
| Maintenance training demonstration module onboard | no |
| Training included with purchase/Avg. time for basic user training | yes (1 training slot)/4 days (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at customer site)/yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes (1 year)/— |
| Distinguishing features (supplied by company) | XT Microslide performs two tests on one slide, which doubles testing output, increases productivity, and fulfills more requests from difficult draws; designed to use single-patient consumables without the need for water, eliminating risk of carryover; MicroSensor technology automates detection of HIL interferences |